Risedronate plus prostaglandin E2 is superior to prostaglandin E2 alone in maintaining the added bone after withdrawal in a non-growing bone site in ovariectomized rats.
Risedronate plus prostaglandin E2 is superior to prostaglandin E2 alone in maintaining the added bone after withdrawal in a non-growing bone site in ovariectomized rats.
复制标题
在切除卵巢的大鼠中，在非生长骨部位撤药后，利塞膦酸盐加前列腺素 E2 优于单独使用前列腺素 E2，以维持增加的骨。
作者：
Liang,HH;Ma,YF;Jee,WS;Pan,Z;Setterberg,RB;McOsker,JE;Li,XJ
研究了利塞膦酸钠和前列腺素E2（PGE2）单独或联合应用对3月龄大鼠胫骨远端（骨骺闭合的非生长骨部位）的影响。6个月大的Sprague-Dawley雌性大鼠要么是ovx，要么是假ovx。大鼠术后立即给予利塞膦酸酯（5 μg/kg/2x/ week）、PGE2（6 mg/kg/d）或利塞膦酸酯+ PGE2治疗60天（对照组），随后60天不给药（非对照组）。测定胫骨远端干骺端松质骨小梁的面积、宽度和数目。排卵120天后，胫骨远端干骺端未见明显骨丢失或结构改变。在治疗和停药期间，单独利塞膦酸钠对骨量没有任何影响。单独使用pge2增加小梁骨量，小梁增厚，小梁数量增加。然而，在停药60天后，一些新形成的骨丢失了。利塞膦酸钠联合pge2治疗增加的骨量与单独使用pge2治疗增加的骨量相同，并且在停药60 d期间，增加的新骨保持不变。这些结果表明，使用利塞膦酸钠和pge2治疗可以在治疗后至少60天保持pge2对骨量的合成代谢作用。
Effects of risedronate and prostaglandin E2(PGE2) alone or in combination on the distal tibia, a non-growing bone site with closed epiphysis at 3 months of age, were studied in ovariectomized (ovx) rats. Six-month-old Sprague-Dawley female rats were either ovx or sham-ovx. Rats were treated immediately after operation either with risedronate (5 μg/kg/2x/wk), PGE2(6 mg/kg/d), or risedronate+ PGE2for 60 days (on-groups) and followed by 60 days without treatment (off-groups). Trabecular area, width and numbers were determined in metaphyseal cancellous bone of the distal tibia. No significant bone loss or structural changes were observed in the distal tibial metaphysis after 120 days of ovx. Risedronate alone did not produce any affect on bone mass during the treatment and the withdrawal periods. PGE2alone increased the trabecular bone mass associated with thickened trabeculae and increased trabecular numbers. However, some of the newly formed bone was lost at the end of 60 days withdrawal. Combination of risedronate and PGE2treatment added the same amount of bone mass as PGE2alone, and the added new bone was maintained during the 60 days withdrawal. These results indicate that treatment with risedronate and PGE2can preserve the anabolic effect of PGE2on bone mass for at least 60 days after treatment.